Joshua D. Stein MD, MS, Bennie H. Jeng, MD, Maria Fernanda Abalem, MD and Emily Patterson, PhD
Launch date: December 22, 2020
Expiration date: December 31, 2021
After attending this course, participants will be able to:
- Define big data and protected health information (PHI).
- Cite a list of available big data sets for eye and vision research.
- Discuss pathways to gain access to big data sets.
- Implement strategies to address data issues that exist within most big data sets.
- Recite options to interrogate big data sets.
- List common tools used to visualize big data sets.
The educational design of this activity addresses the needs of early and mid-career clinicians, clinician-scientists and basic researchers seeking to utilize large clinical data sets to answer research questions aimed at improving our understanding of the visual system and preventing, treating and curing its disorders.
Physician accreditation statement
The Association for Research in Vision and Ophthalmology (ARVO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician credit designation
The Association for Research in Vision and Ophthalmology (ARVO) designates this enduring material activity for a maximum of 9.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
International Attendees: The American Medical Association (AMA) has determined that physicians not licensed in the U.S. who participate in CME activities are eligible for AMA PRA Category 1 Credit™.
American Board of Ophthalmology (ABO) diplomates
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning, Self-Assessment, Improvement in Medical Practice and/or Patient Safety requirements for the American Board of Ophthalmology’s Maintenance of Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit.
Getting the most for Big Data Sets qualifies for Lifelong Learning (Part II). Credits will be reported to the ABO via the ACCME quarterly from March to December 2021. Late requests for credit will not be processed. Learner data will not be shared with any entity other than the ACCME for the purpose of granting MOC credit. Participants will be able to provide the required information for MOC credit tracking on the Overall Meeting Evaluating Form. By providing the required information, attendees will be giving ARVO permission to share their learner data with the ACCME.
European Union of Medical Specialists (UEMS) CME/CPD requirements
European physicians can convert CME credit from Getting the most for Big Data Sets to meet European Union of Medical Specialists (UEMS) CME/CPD requirements.
The American Medical Association has an agreement of mutual recognition of CME credits with the UEMS, the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org.
Certificate of participation
ARVO is accredited to offer AMA PRA Category 1 Credits™ to physicians. All other participants in the CME program may receive a Certificate of Participation that documents the number of CME hours attended* by following the same instructions listed above.
*Some accrediting agencies may award equivalent Continuing Education (CE) credit when presented with a Certificate of Participation from an activity that offered AMA PRA Category 1 Credit™. Check with your accrediting agency for more information.
Instructions to receive credit and/or certificates
Registrants must watch each video and panel discussion in its entirety then complete the activity evaluation form in order to complete the activity and receive credit. A certificate documenting credits awarded will be generated upon completing this activity. The certificate may be downloaded from the My Learning tab, Completed activities list. Partial credit will not be awarded.
Association for Research in Vision and Ophthalmology
Attn: Education Department
5515 Security Lane
Rockville, MD 20852-5007
Email: email@example.com, phone: +220.127.116.1100
This activity provides a forum for the open exchange and discussion of research results and scientific advancements in the field of ophthalmology; however, ARVO makes no representation or warranty as to the truth, originality, or accuracy of the information presented at the courses or in materials distributed in connection with them. Nor are the views expressed by the individual speakers necessarily the views of ARVO. ARVO supports the ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when planning a presentation. The information presented during this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers of use, review of any applicable manufacturer’s product information and comparison with recommendations of other authorities.
Disclaimer off-label use
This activity may contain a discussion of unpublished and/or investigational uses of agents that are not indicated by the FDA. ARVO does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Disclosure of conflicts of interest
ARVO requires instructors, planners, managers and other individuals and their spouse/ partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ARVO for fair, balance, and scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The speakers, planners and managers reported the following financial relationships or relationships to products or devices that they or their spouse/life partners have with commercial interests related to the content of this CME activity:
The following speakers reported financial relationships.
|Name||Commerical interest (nature of the relationship)|
|Pedro Carlos Carricondo MD, PhD||Novartis:(R); Bayer:(R); LatinoFarma:(R); Ophthalmos Rohto:(R); Essilor:(R); Johnson & Johnson:(F); SPOUSE: Novartis(R); Foundation Fighting Blindness:(F)|
|Michael F. Chiang, MD||National Institutes of Health (F); Genentech (F); Novartis:(C); InTeleretina, LLC:(I)|
|Todd Durham, PhD||Foundation Fighting Blindness:(E)*; SPOUSE: Lexitas:(E)|
|Paul Foster, FRCS(Ed), FRCOphth, FRCS(Eng)||DeepMind/Google:(C); Alcon:(F)|
|Takenori Inomata, MD, PhD, MBA||Johnson & Johnson Vison Care:(F); Hogy Medical Co., Ltd:(F); SEED Co., Ltd:(F); Novartis Pharma K.K:(F); Santen Pharmaceutical Co., Ltd:(F); ROHTO Pharmaceutical Co.,Ltd:(F); HOYA Co., Ltd:(F); WAKAMOTO Co., Ltd:(F); Ribomic Co., Ltd:(F); Kowa., Ltd:(F); Lion Corporation:(F); Santen Pharmaceutical Co., Ltd: (C)|
|Pearse Keane, MD, FRCOphth||DeepMind Technologies Inc:(C); Roche:(C); Novartis:(C); Apellis: (C); Allergan:(R); Bayer: (R); Topcon:(R); Heidelberg Engineering: (R); Google:(P); Big Picture Eye Health:(I)|
|Aaron Y. Lee, MD, MSc||Santen:(F); Carl Zeiss Meditec:(F); Novartis:(F); Microsoft:(F); NVIDIA:(F); US Food and Drug Administration:(E)*; Genentech:(C); Verana Health:(C); Topcon:(R)|
|Suzann Pershing, MD||Acumen, LLC:(C); Verana Health:(C)|
|Tyler Hyungtaek Rim, MD, MBA, PhD||Medi Whale: (I); Deep Learning Patents (P)|
|Daniel SW Ting, MD, PhD||Ocutrx:(C); Novartis: (C); Patent holder of a deep learning system: (P); EyRIS, Singapore; (I)|
|Adnan Tufail, BM BS, MD, FRCOphth||Allergan: (C); Bayer:(C,F); Heidelberg Engineering:(C); Kanghong Pharmaceuticals:(C); Novartis: (C, F); Oxurion:(C); Roche:(C); EyeWise:(S); VisionAI:(S); SPOUSE: Heidelberg Engineering:(C)|
*Foundation for Fighting Blindness and US Food and Drug Administration are not an ACCME-defined commercial interests.
The remaining speakers reported no financial relationships:
Sally L. Baxter, MD, MSc, Angela R. Elam, MD, Tina Hernandez-Boussard, MPH, PhD, MS, Alice C. Lorch, MD, MPH, Joshua D. Stein, MS, MD, Brian C. Stagg, MD, Brian L. VanderBeek, MD, MPH, MSCE, Elizabeth Vanner, PhD, Sophia Ying Wang, MD
The following planning committee member reported financial relationships.
Commercial interest (nature of the relationship)
Bennie H. Jeng, MD, Chair-elect
Merck (C), GSK (C), EyeGate (I)
The remaining planning committee members reported no financial relationships:
Joshua D. Stein, MS, MD; Maria Fernanda Abalem, MD, MSc and Emily Patterson, PhD
The following activity managers have reported no financial relationships:
Carlye Armstrong, Cathy Conley, Kathy Cox, Alexis LaCount, Jason Spessard and Mia Williams
The following clinical content reviewer has reported no financial relationships:
Lindsay Scott, PT, DPT, ATC
Category code: Specific financial interests
F (Financial Support) Indicates financial support received from an ACCME-defined commercial interest, in the form of research funding, grants, research materials or in-kind services (e.g., protein sequencing).
I (Personal Financial Interest) Indicates you are an investor in a company or competing company, including an ACCME-defined commercial interest, other than through a mutual or retirement fund.
E (Employment) Indicates you are an employee of an ACCME-defined commercial interest.
C (Consultant) Indicates you are a consultant for an ACCME-defined commercial interest.
P (Patent) Indicates you are an inventor/developer designated on a patent, patent application, copyright or trade secret, whether or not the patent, copyright, etc. is presently licensed or otherwise commercialized, or could be in competition with the technology described.
R (Recipient) Indicates you have received gifts, honoraria, travel reimbursement, patent royalties or any other financial compensation valued in any amount from an ACCME-defined commercial interest.
N (No Commercial Relationship) Indicates there is no commercial relationship relevant to the subject matter of the abstract/article/presentation.
S (non-remunerative) Indicates you have position(s) of influence such as officer, board member, trustee, spokesperson, etc.